Sage Mountain Advisors LLC Sells 271 Shares of Zoetis Inc. (NYSE:ZTS)

Sage Mountain Advisors LLC reduced its stake in Zoetis Inc. (NYSE:ZTS) by 12.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,900 shares of the company’s stock after selling 271 shares during the period. Sage Mountain Advisors LLC’s holdings in Zoetis were worth $310,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Clare Market Investments LLC bought a new stake in Zoetis in the fourth quarter valued at $670,000. Vista Investment Partners II LLC bought a new stake in shares of Zoetis during the fourth quarter worth about $1,879,000. Morton Community Bank increased its position in shares of Zoetis by 4.4% during the fourth quarter. Morton Community Bank now owns 16,694 shares of the company’s stock worth $2,720,000 after acquiring an additional 705 shares in the last quarter. Independent Advisor Alliance increased its position in shares of Zoetis by 25.7% during the fourth quarter. Independent Advisor Alliance now owns 7,211 shares of the company’s stock worth $1,175,000 after acquiring an additional 1,475 shares in the last quarter. Finally, Daiwa Securities Group Inc. increased its position in shares of Zoetis by 4.7% during the fourth quarter. Daiwa Securities Group Inc. now owns 75,874 shares of the company’s stock worth $12,362,000 after acquiring an additional 3,421 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Morgan Stanley decreased their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. Barclays boosted their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Stifel Nicolaus decreased their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, Piper Sandler boosted their target price on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $215.90.

Zoetis Stock Down 1.6 %

ZTS opened at $161.74 on Thursday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The stock has a market cap of $72.43 billion, a price-to-earnings ratio of 29.57, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The company’s 50-day moving average price is $166.92 and its two-hundred day moving average price is $176.44.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.24%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Insider Buying and Selling at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock worth $312,254 over the last three months. 0.16% of the stock is currently owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.